ARGX argenx SE
$882.48▲ +1.51%
Healthcare
Other
After hours
$882.48▲ +0.00%
Oct 27, 4:07 PM ET
Volume 290.1K
Avg Volume (10D) 481.1K
Key Metrics & Fundamentals
Market Cap
$55.50B
P/E Ratio
30.6
Div Yield
0.00%
52W Range
661.85 - 1072.75
% vs 50 MA
-7.23%
% vs 200 MA
3.41%
RSI-14
48.2
MACD Histogram
+7.5400
Beta (1Y vs SPY)
0.39
Gross Rev
$1.72B
Gross Profit
$1.56B
EBITDA
$531.00M
COGS
$165.00M
Operating Exp
$1.07B
Operating Income
$485.00M
EBIT
$485.00M
Pretax Income
$538.00M
Net Income
$506.00M
EPS (Diluted)
7.80
Price & Volume History
Loading chart…
Recent News
argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Run
Simply Wall St. · Oct 25, 2026 12:16 AM ET
argenx (ENXTBR:ARGX) Posted Q3 2026 Results, Is It Fully Priced?
Simply Wall St. · Oct 24, 2026 10:11 PM ET
argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune Myositis
Simply Wall St. · Oct 24, 2026 12:15 PM ET
Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings
Simply Wall St. · Oct 24, 2026 8:11 AM ET
Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer Says
MT Newswires · Oct 23, 2026 1:00 PM ET
Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC Says
MT Newswires · Oct 23, 2026 12:46 PM ET
argenx: 3 Key Takeaways for Long-Term Investors
Motley Fool · Oct 23, 2026 7:25 AM ET
argenx (ARGX) Q3 2026 Earnings Call Transcript
Motley Fool · Oct 23, 2026 4:42 AM ET
argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sales Surge 54% to $1. ...
GuruFocus.com · Oct 22, 2026 5:05 PM ET
Argenx Wavers After A Surprise Testing Setback For Its Bread-And-Butter Drug
Investor's Business Daily · Oct 22, 2026 4:25 PM ET
Financial Overview - Income Statement
Quarterly
Sep 2026
See ARGX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.